Return to Listing

7 result(s) for

PI Name Protocol # Title
Stephen Spurgeon IRB00011766 A Phase Ib Feasibility Study of Personalized Kinase Inhibitor Therapy Combined with Induction in Acute Leukemias who Exhibit in vitro Kinase Inhibitor sensitivity
Raymond Bergan STUDY00015588 Serial Measurements of Molecular and Architectural Responses to Therapy
Uma Borate STUDY00016363 A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Uma Borate STUDY00018059 A Phase I/II, open-label, multi-center study evaluating the safety and efficacy of Ruxolitinib and CPX-351 in combination for the treatment of Secondary Acute Myeloid Leukemia Transformed from Myeloproliferative Neoplasms.
Rachel Cook STUDY00018380 An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
Uma Borate STUDY00019144 A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera
Michael Heinrich STUDY00019801 [NCI CIRB] - S1712 - A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease
 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080